Pharma BD Deal Intelligence
A collaboration deal with no strategic outcome yet—Merck's licensing bet on Protillion's Prot-MaP platform, which screens roughly 1 million protein variants per experiment to fuel AI-driven biologics design, backed by up to $510 million in milestones targeting inflammatory disease programs.
Early platform collaboration; optionality over near-term value
Full analysis, sources & comparables →Protillion Biosciences announces drug discovery collaboration with Merck; undisclosed upfront plus up to $510M in milestones, leveraging the Prot-MaP platform.
Merck inks $510M biobucks data-generation partnership with Protillion.
Merck, Protillion launch AI drug discovery collaboration with up to $510M in milestone payments; initial programs target inflammatory diseases.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
On June 16, 2026, Merck & Co. and Protillion Biosciences announced a drug-discovery collaboration. Protillion is eligible for an undisclosed upfront payment plus up to $510 million in research, development, and commercial milestones. The collaboration applies Protillion's Prot-MaP (Protein Display on a Massively Parallel Array) platform — which can test up to ~1 million protein variants in a single experiment to generate training data for AI-driven protein/biologics design — alongside Merck's drug-discovery capabilities. Initial programs target inflammatory diseases, with potential expansion to additional therapeutic areas.
Discovery-stage collaboration applying Protillion's Prot-MaP (Protein Mapping) megascale data-generation platform to design optimized biologics. The platform generates massive experimental training sets that feed protein-design AI to identify antibodies with sophisticated profiles including pH-dependent 'sweeping' and multi-target specificity, difficult to achieve with conventional methods. Specific indications/targets are undisclosed at signing; Merck holds development rights to multiple resulting therapies.
Merck and Protillion announce a multi-program drug-discovery collaboration applying the Prot-MaP platform to design optimized biologics; undisclosed upfront plus up to $510M in research, development and commercial milestones.
Value is heavily milestone-weighted and discovery-stage; no clinical assets yet. Near-term economics limited to an undisclosed upfront.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck & Co. Inc. / Protillion Biosciences, Inc. (this deal) | 2026 | $510M | 48 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Merck & Co. Inc. / Peloton Therapeutics Inc. | 2019 | $2.2B | 88 |
| Merck & Co. Inc. / AstraZeneca PLC | 2017 | $8.5B | 87 |
| Merck & Co. Inc. / Moderna, Inc. | 2022 | $250M | 86 |
| Merck & Co. Inc. / Moderna, Inc. | 2016 | $250M | 84 |
| Merck & Co. Inc. / Eisai Co., Ltd. | 2018 | $5.8B | 83 |
← Browse all deals · How we score deals
More: 2026 deals · Merck & Co. Inc. deals · Immunology deals